Gastric CancerPhase 1/2NCT01611506
Combination Chemotherapy, Cetuximab and Radiation for Patients With Localized Gastric Cancer
A Phase 1/2 study testing Cetuximab, Capecitabine and Cisplatin in people with Gastric Cancer, run by Dr Anna Dorothea Wagner at 1 site in Switzerland.
Trial summary
RATIONALE: Radiotherapy is currently the most efficient way to induce pathologic responses, which are associated with a favorable prognosis in localized tumors. Novel radiotherapy techniques are associated with significantly less toxicity than traditional radiation protocols and permit to avoid the toxicity to… Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Gastric Cancer
- What is being tested?
- Cetuximab, Capecitabine and Cisplatin
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1 participants
- Where
- 1 siteSwitzerland
- Study dates
- Feb 2012to Dec 2012
- Phase
- Phase 1/2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histologically proven, localized (UICC stage I-II, T1-2, N1-2 or T3N0) or locally advanced (UICC stage III, T3-4, N+) gastric or Siewert Type II and III GE-junction adenocarcinoma. Tumor stage is determined by thoraco-abdominal CT-scan, EUS, as well as mandatory laparoscopy to rule out peritoneal carcinomatosis within 28 days prior to registration.
- ECOG-status 0-1
- Hematologic, liver, and renal function normal
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 12 months after completion of study treatment
Who cannot join
- Peritoneal carcinomatosis, as diagnosed by mandatory laparoscopy or distant metastasis
- Concurrent treatment with other experimental drugs or other anti-cancer therapy, or treatment within a clinical trial within 30 days prior to trial entry
- Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or IV, no myocardial infarction within the last 12 months, unstable angina pectoris, or significant arrhythmia)
- Active or uncontrolled infection.
- Definitive contraindications for the use of corticosteroids as premedication
- Prior systemic (chemo- or targeted) treatment. Prior radiotherapy to the upper abdomen
Show all 14Show fewer
- Any contraindication to treatment with cetuximab, capecitabine or cisplatin
- Any concomitant medication which is contraindicated for use with the trial drugs, such as sorivudin or brivudin
- HER-2 over expression, as determined by immunohistochemistry (IHC 3+) or the combination of IHC and FISH (IHC 2+/FISH+)
- Previous malignancy within 5 years, with the exception of adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer
- Known hypersensitivity against any of the study drugs (cetuximab, cisplatin or capecitabine) or any component of the trial drugs
- Known deficit of dihydropyrimidine dehydrogenase
- Pre-existing peripheral neuropathy > grade I
- Due to known interactions of coumarin antagonists (e.g. warfarin) and capecitabine patients requiring oral anticoagulation should be included in the study only after a switch from oral anticoagulation to low molecular weight heparin
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Integration of Cetuximab, in Combination With Local Radiotherapy, in Perioperative Chemotherapy of Resectable and Locally Advanced Gastric Cancer. A Pilot Phase Ib-trial
RATIONALE: Radiotherapy is currently the most efficient way to induce pathologic responses, which are associated with a favorable prognosis in localized tumors. Novel radiotherapy techniques are associated with significantly less toxicity than traditional radiation protocols and permit to avoid the toxicity to adjacent organs. Established chemotherapy regimens, such as cisplatin and capecitabine, and monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Giving radiation therapy together with cisplatin and cetuximab before surgery aims to induce a pathological response and improve the prognosis after surgery.
PURPOSE: This phase I trial is studying the side effects and best dose of radiation therapy when given together with cisplatin and cetuximab in treating patients who are undergoing surgery for locally advanced gastric cancer.
Read the detailed description
OBJECTIVES:
Primary
- To determine the maximum tolerated dose of radio-chemo-immunotherapy - in patients with localized or locally advanced gastric cancer
Secondary
- To determine the efficacy, as measured by major histopathological response rates (tumor regression grade 1 and 2)
- Metabolic response
- Secondary resectability
- R-0 resection rate
- Surgical morbidity
- Toxicity
- Overall survival
- Time to local and systemic progression after R0-resection
- Feasibility
OUTLINE: Prospective, multicenter, open-label dose escalating phase Ib trial
During induction chemo-immuno-therapy, patients receive cetuximab IV over 1-2 hours on days 1, cisplatin IV over 1 hour on day 1 and capecitabine twice daily per os from the evening of day 1 to the morning of day 15. Treatment repeats every 3 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
Radiotherapy will start after the end of the third cycle of chemotherapy and be performed concomitantly with weekly cetuximab and cisplatin.
Cohorts of 3-6 patients receive escalating doses of radiotherapy (levels of 36/39.6/45 Gy) until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which maximum 3 of 12 patients experience dose-limiting toxicity.
Gastric resection should be performed within 4-6 weeks after completion of neoadjuvant treatment.
4-6 weeks after surgery, a further 3 cycles of chemo-immuno-therapy will be administered if the patient has recovered from surgery and the treatment is considered as feasible by the investigator.
For note: Cisplatin may be replaced by oxaliplatin during induction chemotherapy and postoperative chemotherapy. In case if oxaliplatin is used to replace cisplatin during induction chemotherapy, replacement of cisplatin by oxaliplatin during radio-chemo-immunotherapy may also be considered by the investigator.
Capecitabine may be replaced by infusional 5-FU on day 1-5 every 21 days in case of contraindications to capecitabine.
In case if both cisplatin and capecitabine are to be replaced, 4 cycles of FOLFOX-6 (d-l leucovorin, followed by 5-FU bolus and a continuous infusion of over 46 hours every 2 weeks should be administered in combination with cetuximab).
Patients undergo tumor tissue and blood sample collection periodically for biological studies. Samples are analyzed for major histopathological response.
After completion of study treatment, patients are followed periodically for at least 5 years.
- Conditions
- Gastric Cancer
- Being tested
- Cetuximab, Capecitabine, Cisplatin
- Medical subject headings
- Stomach Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CetuximabBiological
Induction chemotherapy:
Cetuximab 400mg/m2 (loading dose) on day 1 Cetuximab 250mg/m2 weekly thereafter
Followed by:
Cetuximab 250mg/m2 weekly on day 1 during chemoradiation
Postoperative treatment:
3 cycles of Cetuximab 250mg/m2 weekly on day 1
CapecitabineDrug
Induction chemotherapy:
Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle
Postoperative treatment:
Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle
CisplatinDrug
Induction chemotherapy:
Cisplatin 80mg/m2 on day 1 of each 21 day cycle
Followed by:
Cisplatin 30mg/m2 weekly on day 1 during chemoradiation
Postoperative treatment:
Cisplatin 80mg/m2 on day 1 of each 21 day cycle
| Study group | Role | What they receive |
|---|---|---|
| Cetuximab, capecitabine, cisplatin based chemoradiation | Experimental | Induction chemotherapy:
3 cycles (of 3 weeks) with capecitabine, cisplatin and weekly cetuximab: Cetuximab 400mg/m2 (loading dose)on day 1 and 250mg/m2 weekly thereafter, Cisplatin 80mg/m2 on day 1 every three weeks, Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle.
Followed by:
Radio-chemo-immunotherapy:
Cetuximab 250mg/m2 weekly on day 1, Cisplatin 30mg/m2 weekly on day 1, Radiotherapy (dose escalation levels) 36/39.6/45 Gy(according to dose level) in 5 fractions of 1.8 Gy per week
Surgery:
Will be performed 4-6 weeks after neoadjuvant radiochemotherapy
Postoperative treatment:
3 cycles of Chemo-immunotherapy with cetuximab, cisplatin and capecitabine -as described above- will be administered postoperatively if the patient has recovered adequately from surgery and the treatment is considered as feasible by the investigator. Receives: Biological: Cetuximab; Drug: Capecitabine; Drug: Cisplatin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Dose limiting toxicity
Measured: Patients will be evaluated for dose limiting toxicities until four weeks after combined radio-chemo-immunotherapy
Secondary outcomes (9)
Metabolic response
Metabolic response, as measured by F-18-FDG PET-CT measurement of SUVmax
Measured: After 6 weeks of chemo-immunotherapy
Secondary resectability
Measured: Decided by a multidisciplinary team 3-5 weeks after the end of neoadjuvant treatment
Major histopathological response rate
Measured: at surgery 4-6 weeks after end of neoadjuvant therapy
R-0 resection rate
Measured: at surgery 4-6 weeks after the end of neoadjuvant therapy
Surgical morbidity
Measured: within 30 days after surgery
Overall survival
Measured: Measured by median, 1-, 2-, and 3- year survival rates
Time to local and systemic progression after R0-resection
Measured: 5 years after completion of the trial treatement
Feasibility
Measured: Defined as completion of preoperative therapy (including surgery in patients with initially resectable tumors) and being alive 30 days postoperatively.
Toxicity (according to NCI-CTCAE, Version 4.0)
Measured: Within 30 days after completion of the trial treatement
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jun 2012 (estimated)
- Study startFeb 2012
- Primary completionDec 2012
- Study completionDec 2012
Why it stopped: Outcome of EXPAND study (no benefit from adding cetuximab to the first-line chemotherapy in advanced gastric cancer in the overall patient population)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gastric CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 1 participants (actual)
Sponsor and investigators
- Lead sponsor
- Dr Anna Dorothea Wagner
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Dr Anna Dorothea Wagner, Centre Hospitalier Universitaire Vaudois
- Investigators
- Anna Dorothea Wagner, MD, Principal investigator, Centre Hospitalier Universitaire Vaudois
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01611506
- Sponsor's protocol ID
- CHUV-CePO-B354re (gastric)
- Status last verified
- Jan 2013
- First submitted
- 15 May 2012
- Last updated
- 9 Jan 2013
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 9 Jan 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Integration of Cetuximab, in Combination With Local Radiotherapy, in Perioperative Chemotherapy of Resectable and Locally Advanced Gastric Cancer. A Pilot Phase Ib-trial
- ClinicalTrials.gov ID
- NCT01611506
- Acronym / sponsor ID
- CHUV-CePO-B354re (gastric)
- Conditions
- Gastric Cancer
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Outcome of EXPAND study (no benefit from adding cetuximab to the first-line chemotherapy in advanced gastric cancer in the overall patient population)
- Enrolment
- 1 participants (actual)
- Lead sponsor
- Dr Anna Dorothea WagnerUniversity, hospital or other
- Study start
- Feb 2012
- Primary completion
- Dec 2012 (actual)
- Study completion
- Dec 2012 (actual)
- First posted
- 5 Jun 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Radiotherapy is currently the most efficient way to induce pathologic responses, which are associated with a favorable prognosis in localized tumors. Novel radiotherapy techniques are associated with significantly less toxicity than traditional radiation protocols and permit to avoid the toxicity to adjacent organs. Established chemotherapy regimens, such as cisplatin and capecitabine, and monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Giving radiation therapy together with cisplatin and cetuximab before surgery aims to induce a pathological response and improve the prognosis after surgery.
PURPOSE: This phase I trial is studying the side effects and best dose of radiation therapy when given together with cisplatin and cetuximab in treating patients who are undergoing surgery for locally advanced gastric cancer.
Detailed description
OBJECTIVES:
Primary
- To determine the maximum tolerated dose of radio-chemo-immunotherapy - in patients with localized or locally advanced gastric cancer
Secondary
- To determine the efficacy, as measured by major histopathological response rates (tumor regression grade 1 and 2)
- Metabolic response
- Secondary resectability
- R-0 resection rate
- Surgical morbidity
- Toxicity
- Overall survival
- Time to local and systemic progression after R0-resection
- Feasibility
OUTLINE: Prospective, multicenter, open-label dose escalating phase Ib trial
During induction chemo-immuno-therapy, patients receive cetuximab IV over 1-2 hours on days 1, cisplatin IV over 1 hour on day 1 and capecitabine twice daily per os from the evening of day 1 to the morning of day 15. Treatment repeats every 3 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
Radiotherapy will start after the end of the third cycle of chemotherapy and be performed concomitantly with weekly cetuximab and cisplatin.
Cohorts of 3-6 patients receive escalating doses of radiotherapy (levels of 36/39.6/45 Gy) until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which maximum 3 of 12 patients experience dose-limiting toxicity.
Gastric resection should be performed within 4-6 weeks after completion of neoadjuvant treatment.
4-6 weeks after surgery, a further 3 cycles of chemo-immuno-therapy will be administered if the patient has recovered from surgery and the treatment is considered as feasible by the investigator.
For note: Cisplatin may be replaced by oxaliplatin during induction chemotherapy and postoperative chemotherapy. In case if oxaliplatin is used to replace cisplatin during induction chemotherapy, replacement of cisplatin by oxaliplatin during radio-chemo-immunotherapy may also be considered by the investigator.
Capecitabine may be replaced by infusional 5-FU on day 1-5 every 21 days in case of contraindications to capecitabine.
In case if both cisplatin and capecitabine are to be replaced, 4 cycles of FOLFOX-6 (d-l leucovorin, followed by 5-FU bolus and a continuous infusion of over 46 hours every 2 weeks should be administered in combination with cetuximab).
Patients undergo tumor tissue and blood sample collection periodically for biological studies. Samples are analyzed for major histopathological response.
After completion of study treatment, patients are followed periodically for at least 5 years.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Cetuximab, capecitabine, cisplatin based chemoradiation | Experimental | Biological: Cetuximab, Drug: Capecitabine, Drug: CisplatinInduction chemotherapy: 3 cycles (of 3 weeks) with capecitabine, cisplatin and weekly cetuximab: Cetuximab 400mg/m2 (loading dose)on day 1 and 250mg/m2 weekly thereafter, Cisplatin 80mg/m2 on day 1 every three weeks, Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle. Followed by: Radio-chemo-immunotherapy: Cetuximab 250mg/m2 weekly on day 1, Cisplatin 30mg/m2 weekly on day 1, Radiotherapy (dose escalation levels) 36/39.6/45 Gy(according to dose level) in 5 fractions of 1.8 Gy per week Surgery: Will be performed 4-6 weeks after neoadjuvant radiochemotherapy Postoperative treatment: 3 cycles of Chemo-immunotherapy with cetuximab, cisplatin and capecitabine -as described above- will be administered postoperatively if the patient has recovered adequately from surgery and the treatment is considered as feasible by the investigator. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Histologically proven, localized (UICC stage I-II, T1-2, N1-2 or T3N0) or locally advanced (UICC stage III, T3-4, N+) gastric or Siewert Type II and III GE-junction adenocarcinoma. Tumor stage is determined by thoraco-abdominal CT-scan, EUS, as well as mandatory laparoscopy to rule out peritoneal carcinomatosis within 28 days prior to registration.
- ECOG-status 0-1
- Hematologic, liver, and renal function normal
- Not pregnant or nursing
- Negative pregnancy test
Key exclusion criteria (14 listed)
- Peritoneal carcinomatosis, as diagnosed by mandatory laparoscopy or distant metastasis
- Concurrent treatment with other experimental drugs or other anti-cancer therapy, or treatment within a clinical trial within 30 days prior to trial entry
- Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or IV, no myocardial infarction within the last 12 months, unstable angina pectoris, or significant arrhythmia)
- Active or uncontrolled infection.
- Definitive contraindications for the use of corticosteroids as premedication
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CetuximabInduction chemotherapy: Cetuximab 400mg/m2 (loading dose) on day 1 Cetuximab 250mg/m2 weekly thereafter Followed by: Cetuximab 250mg/m2 weekly on day 1 during chemoradiation Postoperative treatment: 3 cycles of Cetuximab 250mg/m2 weekly on day 1 | Biological | Cetuximab, capecitabine, cisplatin based chemoradiation |
| CapecitabineInduction chemotherapy: Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle Postoperative treatment: Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle | Drug | Cetuximab, capecitabine, cisplatin based chemoradiation |
| CisplatinInduction chemotherapy: Cisplatin 80mg/m2 on day 1 of each 21 day cycle Followed by: Cisplatin 30mg/m2 weekly on day 1 during chemoradiation Postoperative treatment: Cisplatin 80mg/m2 on day 1 of each 21 day cycle | Drug | Cetuximab, capecitabine, cisplatin based chemoradiation |
Primary outcome
Dose limiting toxicity
Time frame: Patients will be evaluated for dose limiting toxicities until four weeks after combined radio-chemo-immunotherapy
9 secondary outcomes
Metabolic response
Time frame: After 6 weeks of chemo-immunotherapy
Secondary resectability
Time frame: Decided by a multidisciplinary team 3-5 weeks after the end of neoadjuvant treatment
Major histopathological response rate
Time frame: at surgery 4-6 weeks after end of neoadjuvant therapy
R-0 resection rate
Time frame: at surgery 4-6 weeks after the end of neoadjuvant therapy
Surgical morbidity
Time frame: within 30 days after surgery
Overall survival
Time frame: Measured by median, 1-, 2-, and 3- year survival rates
Time to local and systemic progression after R0-resection
Time frame: 5 years after completion of the trial treatement
Feasibility
Time frame: Defined as completion of preoperative therapy (including surgery in patients with initially resectable tumors) and being alive 30 days postoperatively.
Toxicity (according to NCI-CTCAE, Version 4.0)
Time frame: Within 30 days after completion of the trial treatement
Results and safety
The study was stopped early (reason given: Outcome of EXPAND study (no benefit from adding cetuximab to the first-line chemotherapy in advanced gastric cancer in the overall patient population)). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jan 2013.
Related trials for Gastric Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
Not yet recruitingPhase 1
GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
Gastric Cancer (GC)
RecruitingPhase 3
A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.
Gastric, Esophagogastric Junction
Active, not recruitingEarly Phase 1
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
B-ALL, DLBCL
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Anna Dorothea Wagner, MD principal investigator
Centre Hospitalier Universitaire Vaudois
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing Cetuximab, Capecitabine and Cisplatin in people with Gastric Cancer, run by Dr Anna Dorothea Wagner at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 9 Jan 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early (reason given: Outcome of EXPAND study (no benefit from adding cetuximab to the first-line chemotherapy in advanced gastric cancer in the overall patient population)). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Dose limiting toxicity (time frame: Patients will be evaluated for dose limiting toxicities until four weeks after combined radio-chemo-immunotherapy). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jan 2013.